TEM sees modest Q3 reimbursement gains, but FDA and ADLT pathways for xT, xF and xR assays could narrow its pricing gap over 2025-2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback